Recruiting
Post transplant lymphoproliferative disorder+1
RecruitingInvestigationalNo placebo
Study of Tabelecleucel for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Transplant Treatment Failure
InvestigationalNo placebo
- Disease:Post transplant lymphoproliferative disorderEpstein-Barr virus associated lymphoproliferative disorder
- Substances:Tabelecleucel
Countries:
Austria
Austria- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Tabelecleucel
- Sponsor:Pierre Fabre Medicament



